surmount-1 tirzepatide trial obesity without diabetes π Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but diabetes. Researchers Tirzepatide and blood pressure reduction:
Description
Enhanced Fat Burning: Tirzepatide also has the exciting potential to enhance fat-burning in the body

doi: 10.1001/jama.2014.16107

Tirzepatide also demonstrated a generally favorable safety profile with most side effects gastrointestinal in nature

For others, the journey might be more gradual, needing consistent support and lifestyle adjustments
"Yeah, no
These will show you what to expect, how to manage mild side effects, and how to get the most benefit from your tirzepatide treatment
